Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial
Authors:
- Ulrich GüllerUGUlrich Güller
- Stefanie HayozSHStefanie Hayoz
- Daniel HorberDHDaniel Horber
- Wolfram JochumWJWolfram Jochum
- Sara De DossoSDSara De Dosso
- Dieter KoeberleDKDieter Koeberle
- Sabina SchacherSSSabina Schacher
- Roman InauenRIRoman Inauen
- Michael StahlMSMichael Stahl
- Thierry DelaunoitTDThierry Delaunoit
- Thomas EttrichTEThomas Ettrich
- György BodokyGBGyörgy Bodoky
- 11 March 2025
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (15) , 3142-3149
Abstract
Purpose: We assessed the benefit of adjuvant aspirin in patients with resected phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)–mutated colon cancer. Patients and Methods: This was a phase III, prospective, randomized, placebo-controlled, double-blind, multicenter, and multinational trial. Patients with resected colon cancer stage II and III harboring an activating PIK3CA mutation were included. Because of financial constraints, the trial was prematurely closed. Randomization was 2:1 to aspirin 100 mg versus placebo daily for 3 years. The primary endpoint was disease-free survival (DFS). Secondary endpoints included the time to disease recurrence (TTR), overall survival, and adverse events. Results: Overall, 1,040 patients were screened for PIK3CA mutations, with 112 randomized to aspirin (N = 74) and placebo (N = 38). The median age was 66 years, and 42.9% were female. After a median follow-up of 4 years, 19 DFS events occurred, including 10 in the aspirin and nine in the placebo arm. The HR for DFS was 0.57 [90% confidence interval (CI), 0.27–1.22], in favor of aspirin (P = 0.11). DFS rates at 5 years were 86.5% (90% CI, 77.7%–92.0%) in the aspirin and 72.9% (90% CI, 55.7%–84.3%) in the placebo arm. The HR for TTR was 0.49 (90% CI, 0.21–1.19, P = 0.089) in favor of aspirin. No patient experienced aspirin-related serious adverse events. Conclusions: The SAKK 41/13 is the first randomized trial to provide clinical evidence of a protective effect of adjuvant aspirin in patients with resected PIK3CA-mutant colon cancer, with clinically relevant DFS and TTR improvements. Although results were not statistically significant because of premature study closure, adjuvant aspirin warrants individual consideration in patients with resected PIK3CA-mutant colon cancer stage II and III. See related commentary by Drew et al., p. 3107Keywords
All Related Versions
Funding Information
- Swiss National Foundation
- Krebsliga Schweiz
- Promedica Stiftung
- Fédération Francophone de la Cancérologie Digestive
This publication has 25 references indexed in Scilit:
- Aspirin Use and Survival After Diagnosis of Colorectal CancerJAMA, 2009
- Cyclooxygenase‐2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancerInternational Journal of Cancer, 2009
- Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3Journal of Clinical Oncology, 2009
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsThe Lancet, 2009
- Caveats in the interpretation of the surgical literatureBritish Journal of Surgery, 2008
- Aspirin and the Risk of Colorectal Cancer in Relation to the Expression of COX-2New England Journal of Medicine, 2007
- Combined Inhibitory Effects of Green Tea Polyphenols and Selective Cyclooxygenase-2 Inhibitors on the Growth of Human Prostate Cancer Cells Both In vitro and In vivoClinical Cancer Research, 2007
- A Prospective Study of Aspirin Use and the Risk for Colorectal AdenomaAnnals of Internal Medicine, 2004
- A Randomized Trial of Aspirin to Prevent Colorectal Adenomas in Patients with Previous Colorectal CancerNew England Journal of Medicine, 2003
- Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysisBMJ, 2000